1PAYA C V, HERMANS P E, WASHINGTON J A D, et al. Incidence, distribution and outcome of episodes of infection in 100 orthotopic liver transplantations [J]. Mayo Clin Proc, 1989, 64 (5) : 555 -564.
2FALAGAS M E, SNYDMAN D R, GRIFFITH J, et al. Effect of cytomegalovirus infection status on first - year mortality rates among orthotopic liver transplant recipients [J]. Ann Internal Med, 1997, 126(4): 275-279.
3HOPPE L, MARRONI C A, BRESSANE R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients[J]. Transplant Pro, 2006, 38 (6) : 1 922 -1 923.
4LJUNGMAN P, GRIFFITHS P, PAYA C, et al. Definitions of cytomegalovirus infection and disease in transplant recipients [J]. Clin Infect Dis, 2002, 34 (8) : 1 094 - 1 097.
5KALIL A C, LEVITSKY J, LYDEN E, et al. Meta - Analysis : The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients[J]. Ann Intern Med, 2005, 143: 870 - 880.
6GANE E, SALIBA F, VALDECASAS G J, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver - transplant recipients [J]. Lancet, 1997, 350(12) : 1 729 -1 733.
7SEEHOFER D, RAYES N, NEUMANN UP, et al. Changing impact of cytomegalovirus in liver transplantation - a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis[J]. Transpl Intern, 2005, 18(8) : 941 -948.
8PAYA C V, WILSON J A, ESPY M J, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo - controlled trial[J]. J Inf Dis, 2002, 185(4) : 854 -860.
9DiAZ - PEDROCHE, CARMEN. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high - risk seropositive solid - organ transplant recipients [ J ]. Clin Transplant, 2006, 82 ( 1 ) : 30 - 35.
10SINGH N, WANNSTEDT C, KEYES L, et al. Efficacy of preemptive therapy with valganciclovir for cytomegalovirus(CMV) in CMV - seronegative liver transplant recipients with CMV -seorpositive donors( R -/D + )[J]. Transplantation, 2005, 79(1): 85-90.
